Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

• Status: Completed
• Trial end date: 2003-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Must have a clinical diagnosis of Alzheimer's Disease

• Must be at least 50 years of age

• Must fluently read and speak English

• Must have a reliable caregiver

Exclusion Criteria:

• Has serious health problems other than Alzheimer's Disease

• Cannot swallow whole pills

• Has had a menstrual period in the last two years

• Takes insulin for diabetes

• Has taken Aricept, Reminyl, or Exelon in the last 5 weeks